Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006014714 | Oral cavity | LP | regulation of posttranscriptional gene silencing | 25/4623 | 52/18723 | 2.15e-04 | 2.33e-03 | 25 |
GO:006071113 | Oral cavity | LP | labyrinthine layer development | 22/4623 | 44/18723 | 2.51e-04 | 2.63e-03 | 22 |
GO:006014814 | Oral cavity | LP | positive regulation of posttranscriptional gene silencing | 17/4623 | 31/18723 | 3.09e-04 | 3.15e-03 | 17 |
GO:001000111 | Oral cavity | LP | glial cell differentiation | 78/4623 | 225/18723 | 4.82e-04 | 4.52e-03 | 78 |
GO:009892714 | Oral cavity | LP | vesicle-mediated transport between endosomal compartments | 21/4623 | 43/18723 | 5.18e-04 | 4.82e-03 | 21 |
GO:007030216 | Oral cavity | LP | regulation of stress-activated protein kinase signaling cascade | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:003021613 | Oral cavity | LP | keratinocyte differentiation | 51/4623 | 139/18723 | 1.05e-03 | 8.84e-03 | 51 |
GO:000189217 | Oral cavity | LP | embryonic placenta development | 33/4623 | 82/18723 | 1.34e-03 | 1.07e-02 | 33 |
GO:004502213 | Oral cavity | LP | early endosome to late endosome transport | 19/4623 | 40/18723 | 1.44e-03 | 1.14e-02 | 19 |
GO:000991315 | Oral cavity | LP | epidermal cell differentiation | 69/4623 | 202/18723 | 1.53e-03 | 1.19e-02 | 69 |
GO:003287216 | Oral cavity | LP | regulation of stress-activated MAPK cascade | 66/4623 | 192/18723 | 1.60e-03 | 1.23e-02 | 66 |
GO:006042513 | Oral cavity | LP | lung morphogenesis | 22/4623 | 50/18723 | 2.18e-03 | 1.58e-02 | 22 |
GO:00609685 | Oral cavity | LP | regulation of gene silencing | 32/4623 | 81/18723 | 2.24e-03 | 1.62e-02 | 32 |
GO:19037981 | Oral cavity | LP | regulation of production of miRNAs involved in gene silencing by miRNA | 13/4623 | 25/18723 | 2.98e-03 | 2.04e-02 | 13 |
GO:004830811 | Oral cavity | LP | organelle inheritance | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
GO:004831311 | Oral cavity | LP | Golgi inheritance | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
GO:003134615 | Oral cavity | LP | positive regulation of cell projection organization | 109/4623 | 353/18723 | 4.59e-03 | 2.93e-02 | 109 |
GO:00709201 | Oral cavity | LP | regulation of production of small RNA involved in gene silencing by RNA | 13/4623 | 26/18723 | 4.62e-03 | 2.93e-02 | 13 |
GO:200064111 | Oral cavity | LP | regulation of early endosome to late endosome transport | 10/4623 | 18/18723 | 4.91e-03 | 3.06e-02 | 10 |
GO:000756914 | Oral cavity | LP | cell aging | 46/4623 | 132/18723 | 5.64e-03 | 3.40e-02 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2 | SNV | Missense_Mutation | | c.5158G>A | p.Gly1720Ser | p.G1720S | P11137 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | novel | c.5438N>G | p.Thr1813Ser | p.T1813S | P11137 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP2 | SNV | Missense_Mutation | | c.1633N>C | p.Asp545His | p.D545H | P11137 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.771) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
MAP2 | SNV | Missense_Mutation | rs780652765 | c.4724G>A | p.Arg1575Gln | p.R1575Q | P11137 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MAP2 | SNV | Missense_Mutation | | c.2813A>G | p.His938Arg | p.H938R | P11137 | protein_coding | tolerated_low_confidence(0.89) | benign(0.038) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP2 | SNV | Missense_Mutation | | c.2342N>T | p.Gln781Leu | p.Q781L | P11137 | protein_coding | deleterious(0) | benign(0.129) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
MAP2 | SNV | Missense_Mutation | novel | c.2427N>T | p.Met809Ile | p.M809I | P11137 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2 | SNV | Missense_Mutation | novel | c.4259N>T | p.Ser1420Leu | p.S1420L | P11137 | protein_coding | deleterious(0) | benign(0.015) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
MAP2 | SNV | Missense_Mutation | | c.1849N>A | p.Asp617Asn | p.D617N | P11137 | protein_coding | deleterious_low_confidence(0.01) | benign(0.31) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP2 | SNV | Missense_Mutation | novel | c.343N>G | p.Gln115Glu | p.Q115E | P11137 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.977) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |